Hershey: The Bear Case Just Melted, I'm Upgrading To Bullish While Yielding 3.32%
Source: seekingalpha.com

Hershey (HSY) was upgraded to bullish as cocoa prices face deflation and logistics improved. The article notes a Q2 double beat, with full-year guidance raised, and highlights shares trading at 17.7x 2027 EPS with a 3.32% dividend yield. Management maintained dividend growth despite EPS declines, while expanding margins through ongoing commodity headwinds—driving a more constructive outlook.
Analysis
The market mechanism here is not just cheaper cocoa; it is the combination of lower input cost, less freight friction, and a management team that has already proven it can hold price without losing the category. That matters because the earnings delta should flow through with a lag: hedges and inventory will delay the full benefit for a quarter or two, but once the cost stack resets, incremental gross margin can re-rate faster than consensus expects. In that setup, HSY is more of a cash-flow compounder than a simple commodity beta name.
Relative winners are likely HSY versus broader staples and more internationally exposed chocolate peers. Companies with weaker brand power or a less efficient supply chain will be more tempted to use cocoa relief to compete on price, which could cap industry-wide margin expansion; HSY’s domestic shelf presence and simpler operating model should help it defend mix better than peers. The dividend is also a meaningful floor for the stock: if free cash flow inflects while payout growth remains intact, downside investors can underwrite the name as a defensive yield-plus-revision story.
The main risk is that the consensus is extrapolating a commodity tailwind that can reverse quickly if West African supply tightens again or if FX/logistics noise resurfaces. The thesis is falsified if the next one to two quarters fail to show gross margin expansion or if scanner data shows volume erosion from price resistance. Over 6-18 months, the key question is whether the current multiple already reflects normalized margins; if yes, upside becomes more about earnings revisions than further rerating.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
Key Decisions for Investors
- Go long HSY on any post-earnings consolidation; target a 6-12 month hold where margin normalization, not multiple expansion, drives return. Risk/reward improves if the stock stays near the current 17-18x forward range while guidance revisions continue upward.
- Pair trade: long HSY / short MDLZ as a relative-value expression of cocoa deflation plus stronger operating leverage. This works best over the next 1-3 quarters if HSY shows faster margin expansion while MDLZ’s more diversified mix dampens the benefit.
- Use a 6-9 month call spread instead of outright stock if you want upside participation with limited carry cost; the dividend reduces urgency to own delta outright. This is most attractive if implied volatility stays muted after the guidance raise.
- Set a watch item on gross margin and inventory turns in the next two earnings prints; if margin does not expand despite lower cocoa, exit the thesis. The key falsifier is continued price resistance without volume recovery.
More News
- Copper is outshining gold this year. Investors say the rally can survive an AI correction
- 'Cannot play hide and seek': Singapore minister's warning over haze sends agricultural stocks lower
- BlackRock, GIC among investors chasing Indian telecom major Jio's IPO as anchor bids top $26 billion
- Nscale, Anthropic Eye $45 Billion Cloud Deal as AI Trade Rebounds
- Volkswagen bet on Xpeng to save its China business. It’s not going to plan
- Gartner analyst behind tech rout: AI returns are not yet large enough to justify neocloud build-out
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AlphaSense Pricing: What Public Contract Data Shows in 2026
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market